10X Competitors
| TXG Stock | USD 19.06 0.22 1.14% |
10X Genomics vs Certara Correlation
Good diversification
The correlation between 10X Genomics and CERT is -0.16 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding 10X Genomics and CERT in the same portfolio, assuming nothing else is changed.
Moving against 10X Stock
The current Return On Tangible Assets is estimated to decrease to -0.19. The current Return On Capital Employed is estimated to decrease to -0.23. At this time, 10X Genomics' Debt To Assets are most likely to slightly decrease in the upcoming years.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of 10X Genomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
10X Genomics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between 10X Genomics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of 10X and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of 10X Genomics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between 10X Stock performing well and 10X Genomics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze 10X Genomics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SDGR | 2.21 | (0.71) | 0.00 | (0.35) | 0.00 | 3.86 | 15.22 | |||
| PGNY | 2.44 | 0.34 | 0.10 | 0.53 | 2.97 | 5.30 | 35.40 | |||
| GRDN | 1.95 | 0.09 | 0.05 | 0.11 | 2.43 | 4.77 | 13.96 | |||
| TDOC | 2.17 | (0.95) | 0.00 | (0.40) | 0.00 | 3.32 | 15.93 | |||
| OMDA | 2.97 | (0.86) | 0.00 | (0.92) | 0.00 | 4.61 | 19.12 | |||
| JANX | 3.19 | (0.81) | 0.00 | (0.72) | 0.00 | 7.88 | 63.52 | |||
| OMCL | 1.73 | 0.45 | 0.26 | 0.42 | 1.36 | 5.25 | 13.02 | |||
| SION | 3.09 | 0.24 | 0.03 | (0.85) | 4.74 | 7.92 | 31.39 | |||
| NUVB | 4.06 | 0.36 | 0.07 | 0.36 | 4.61 | 7.33 | 68.61 | |||
| CERT | 2.39 | (0.59) | 0.00 | (0.47) | 0.00 | 4.75 | 25.45 |
Cross Equities Net Income Analysis
Compare 10X Genomics and related stocks such as Schrodinger, Progyny, and Guardian Pharmacy Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SDGR | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (28.4 M) | (24.6 M) | (24.5 M) | (100.4 M) | (149.2 M) | 40.7 M | (187.1 M) | (168.4 M) | (160 M) |
| PGNY | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | 661 K | (8.6 M) | 46.5 M | 65.8 M | 30.4 M | 62 M | 54.3 M | 62.5 M | 32.8 M |
| GRDN | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 21.7 M | 19.9 M | 16.3 M | 35.4 M | 23.9 M | (87.3 M) | (78.6 M) | (74.6 M) |
| TDOC | (6 M) | (6 M) | (6 M) | (6 M) | (17 M) | (58 M) | (74.2 M) | (106.8 M) | (97.1 M) | (98.9 M) | (485.1 M) | (428.8 M) | (13.7 B) | (220.4 M) | (1 B) | (901.1 M) | (946.2 M) |
| OMDA | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (67.5 M) | (47.1 M) | (54.2 M) | (56.9 M) |
| JANX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (6.8 M) | (32.6 M) | (54.2 M) | (58.3 M) | (69 M) | (62.1 M) | (59 M) |
| OMCL | (20.8 M) | 10.4 M | 16.2 M | 24 M | 30.5 M | 30.8 M | 603 K | 20.6 M | 37.7 M | 61.3 M | 32.2 M | 77.8 M | 5.6 M | (20.4 M) | 12.5 M | 14.4 M | 17.6 M |
| SION | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (47.3 M) | (61.7 M) | (55.5 M) | (58.3 M) |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (33.6 M) | (41.7 M) | (86.8 M) | (104.2 M) | (75.8 M) | (567.9 M) | (511.1 M) | (485.6 M) |
| CERT | (33.3 M) | (33.3 M) | (33.3 M) | (33.3 M) | (33.3 M) | (33.3 M) | (33.3 M) | (33.3 M) | (33.3 M) | (8.9 M) | (49.4 M) | (13.3 M) | 14.7 M | (55.4 M) | (12.1 M) | (13.9 M) | (14.6 M) |
10X Genomics and related stocks such as Schrodinger, Progyny, and Guardian Pharmacy Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in 10X Genomics financial statement analysis. It represents the amount of money remaining after all of 10X Genomics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.10X Genomics Competitive Analysis
The better you understand 10X Genomics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, 10X Genomics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across 10X Genomics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
10X Genomics Competition Performance Charts
Five steps to successful analysis of 10X Genomics Competition
10X Genomics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by 10X Genomics in relation to its competition. 10X Genomics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of 10X Genomics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact 10X Genomics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to 10X Genomics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your 10X Genomics position
In addition to having 10X Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Natural Foods Thematic Idea Now
Natural Foods
Companies producing natural foods including dairy products and different types of meets. The Natural Foods theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Natural Foods Theme or any other thematic opportunities.
| View All Next | Launch |
Check out 10X Genomics Correlation with its peers. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Can Life Sciences Tools & Services industry sustain growth momentum? Does 10X have expansion opportunities? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating 10X Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets | Return On Equity |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, 10X Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.